CStone Pharmaceuticals
CStone Pharmaceuticals has 1 licensing announcement in this dataset, dated 2025-07-08.
- Country / operating region
- China
- Ticker
- 02616.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.cstonepharma.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| sugemalimab | PD-L1 | antibody | 查無 | 2025-07-08 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| sugemalimab | Approved in EU / UK for selected NSCLC indications (at source date) | — | 查無 | 查無 | 2025-07-08 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2025-07-08 | Istituto Gentili | sugemalimab | 查無 | 查無 | 查無 | ≤ USD 192.5m | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Istituto Gentili | Western Europe and the United Kingdom; countries enumerated in source | Supply revenue close to 50% of net sales; not classified as a royalty rate. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無